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1. Introduction 
1.1 Tobacco smoke exposure and cardiovascular disease 
More than 1 in every 10 cardiovascular deaths in the world during the year 2000 were 
attributable to smoking, demonstrating that it is an important preventable cause of 
cardiovascular mortality (Ezzati et al., 2005). It has been clearly established that exposure to 
environmental tobacco smoke increases the risk of cardiovascular disease among persons 
who have never smoked  (Steenland, 1992).  The cardiovascular effects of secondhand smoke 
are nearly as large as those confronting the principal smoker (Barnoya & Glantz, 2005).   
Non-smokers living with smokers have about a 25% increase in risk of death from heart 
disease and are more likely to suffer a stroke. Exposure to secondhand smoke may increase 
the risk of heart disease by non-smokers as much as 60% (Whincup et al., 2004).   In  2004, 
Ong & Glantz estimated that only about 69% of U.S. indoor workers were covered by a 
smoke-free workplace policy. Making all workplaces smoke free as been accomplished for 
the commercial aircraft industry (Repace, 2004) would in one year prevent about 1500 
myocardial infarctions and 350 strokes, and result in nearly 49 million dollars in savings in 
direct medical costs. These estimates are supported by reports of reduced incidence of 
admissions for myocardial infarction associated with smoking bans (Sargent  et al.,  2004). 
The cardiovascular effects of tobacco smoke exposure have been summarized in several 
excellent reviews (for example, see Barnoya and Glantz, 2005). Among the strongest 
pathophysiological correlates of tobacco smoking are accelerated endothelial dysfunction 
(Puranik & Celermajer, 2003) and acute clinical events, the latter being largely thrombotic 
(Ambrose & Barus, 2004).  Recent studies indicate that increased oxidative stress is a 
potential mechanism for initiating cardiovascular dysfunction (Yang et al., 2004; Talukder et 
al, 2011). Tobacco smoke has also been demonstrated to increase inflammatory markers in 
patients exposed to secondhand smoke, including homocysteine, C-reactive protein, 
fibrinogen, and oxidized LDL cholesterol, (Panagiotakos et al., 2004) suggesting that an 
increased inflammatory response may contribute to accelerated atherosclerosis.  Clearly, the 
incidence of ischemic coronary and peripheral vascular disease is increased in patients 
exposed to tobacco smoke, either as smokers or through exposure to secondhand tobacco 
smoke (Ambrose & Barus, 2004; Benowitz, 2003; Law & Wald, 2003; Burns, 2003; Leone et 
al.,  2004). The cardiovascular  effects of tobacco smoke exposure are summarized in Table l. 
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Table 1. Cardiovascular effects of tobacco smoke exposure. 
1.2 Tobacco smoke exposure and heart failure 
National hospital discharge surveys estimate that 4.8 million Americans have heart failure, 
which has become an increasingly frequent reason for inpatient admission (Ho et al., 1993). 
One recent study estimated that among individuals aged 55 and older almost 1 in 3 will 
develop heart failure during their remaining lifespan. Heart failure is a fatal disease, with only 
35% surviving 5 years after diagnosis (Bleumink et al., 2004). Coronary disease and diabetes 
mellitus along with hypertension are the leading causes of heart failure in the United States 
and it is therefore not surprising that tobacco smoke exposure has been identified as an 
independent risk factor for developing heart failure (Kannel et al., 1994; He et al., 2001). 
However, in at least 5% of patients, the cause of heart failure is initially unknown 
(Baldasseroni et al., 2002) and it has been estimated that myocarditis or inflammation of the 
heart muscle, may account for some 9% of these cases (Felker et al., 2000).  Although estimates 
vary, these figures indicate that hundreds of thousands of Americans and millions of patients 
worldwide with heart failure may have myocarditis as a primary or exacerbating cause. The 
true incidence of myocarditis from any cause among the general population is unknown and 
most patients do not develop clinical manifestations of heart failure (Olinde & O’Connell, 
1994). However, the Myocarditis Treatment Trial in which endomyocardial biopsy was 
performed in over 2,200 patients with unexplained heart failure of less than two years duration 
indicated a prevalence of 10%, implicating myocarditis as a potential cause of heart failure in 
hundreds of thousands of patients (Mason et al., 1995).  Since only around 5% of patients 
systemically infected with a cardiotropic virus (Coxsakie ǃ) may develop cardiac involvement, 
it is important to determine what factors may increase the risk of cardiac involvement (Grist & 
Bell, 1969; Gerzen et al., 1972; Rodeheffer & Gersh, 1996).  
1.3 Catecholamines exacerbate myocarditis  
Evidence from several different sources indicates that catecholamines may exacerbate viral 
myocarditis in animals and patients. A variety of sympathomimetic agents have been reported 
to induce or exacerbate myocarditis (Table 2).  It is also important to note that nicotine has 
www.intechopen.com
Exacerbation of Viral Myocarditis by  
Tobacco Smoke: The Catecholamine Hypothesis 
 
171 
been shown to increase catecholamine levels in the blood (Wong et al, 2007). The most direct 
evidence arises from carefully controlled studies of murine myocarditis indicting that 
hypercatecholaminergeic states, secondary to pheochromocytoma and during infusion with 
sympathomimetic drugs, can cause or significantly exacerbate myocarditis (Cho et al., 1987; 
Van Vliet et al., 1966; Bindoli et al., 1992; Kammermeier & Grobecker, 1995; Davila et al., 1995; 
Prichard et al., 1991; Brown & O’Connell, 1995; Siltanen et al., l982; Haft, 1974; Noda, 1970; 
Morin & Cote, 1972; Seta et al., 1997; Nash & Carter, 1967; Karch, 1987; Krentz et al.,  2001; 
Rezkalla et al., 1988).   Reports of a prospective study by Karch (Karch, 1987) showed 
significantly elevated levels of epinephrine and norepinephrine in a group of patients who 
presented with cardiac symptoms immediately after using cocaine.  Moreover, sympatholytic 
agents and states may ameliorate the manifestations of myocarditis and decrease mortality, 
although this effect is controversial (Rezkalla et al., 1988; Anandasabapathy & Frishman, 1998; 
Mehes et al., 1966; Dunn & Vickers, 1994).  We have shown a beneficial effect of beta blockade, 
ameliorating cocaine and catecholamine exacerbation of myocarditis in a murine model (Wang 
et al., 2005). It is provocative to consider that many of the interventions shown to ameliorate 
viral myocarditic pathgenicity, including calcium channel blockers, act predominantly to 
attenuate sympathomimetic effects on the heart (Dong et al., 1992; Hiraoka et al., 1996; 
Lowenstein et al., 1996; Wang et al., 1997; Keaney et al., 1996).  Additional evidence includes 
the observation that, among commonly abused substances in the general population (alcohol, 
nicotine, caffeine, marijuana, and cocaine), cocaine has been most strongly associated with an 
increased incidence of myocarditis, suggesting that its unique sympathomimetic properties, 
not shared with these other agents, may be the causative factor. Moreover, in the clinical area, 
it has been accepted clinical practice for many years to restrict the activities of patients with 
myocarditis, primarily based on animal studies and circumstantial clinical evidence in man 
that exercise exacerbates the disease (Abelmann, 1966; Cabinian et al., 1990; Gatmaitan et al., 
1970; Friman et al., 1983; Kiel et al., 1989; Tilles et al., 1964; Elson & Abelmann, 1965; Hosenpud 
et al., 1987). In addition to directly increasing the work of the heart, normal exercise is 
associated with a marked increase in circulating catecholamine levels (Cabinian et al., 1990; 
Gatmaitan et al., 1970; Friman et al., 1983; Kiel et al., 1989). While the cardiac effects of 
sympathomimetic drugs and interventions using sympatholytic agents require additional 
testing in animal models of myocarditis and in man, the available evidence points to 
catecholaminergic effects in the development of myocarditis. 
1.4 Adrenergic activation by cigarette smoke 
It has been estimated that there are over 4,000 chemical constituents in cigarette smoke. Of 
these, about 400 have been measured or estimated in mainstream or sidestream smoke; of 
the 400, a significant amount of toxicology data exists for less than 100 (Fowles & Bates, 
2000). Nicotine is the most comprehensively studied constituent of cigarette smoke, and has 
been shown to act primarily on nicotinic acetylcholine receptors in autonomic ganglia and in 
the brain (Benowitz, 2008; Mobascher & Winterer, 2008). This results in activation of the 
sympathetic nervous system, increasing the release of epinephrine (EPI) and norepinephrine 
(NE) from adrenergic nerve endings and the adrenal medulla, both systemically and into the 
local milieu of adrenergically innervated organs, including the heart (Haass & Kϋbler, 1997; 
Adamopoulos, et al., 2008; Shinozaki et al., 2008). Cigarette smoke also contains monoamine 
oxidase inhibitors (Cooper & Magwere, 2008; Fowles & Bates, 2000; Herraiz et al., 2005). 
Cigarette smoke has been shown to increase norepinephrine and epinephrine levels with 
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Table 2. Sympathomimetic agents that may initiate or exacerbate myocarditis. 
associated increases in heart rate, blood pressure and coronary vasoconstriction (Haass & 
Kϋbler, 1997, Adamopoulos et al., 2008, Shinozaki et al., 2008). Nicotine may also potentiate 
catecholamine actions, perhaps via effects on nitric oxide synthesis or release (Haass & 
Kϋbler, 1997). The adrenergic actions of nicotine can be attenuated or blocked by 
administration of beta-adrenergic antagonists, although it has been proposed that the drug 
may act by additional mechanisms to activate the beta-adrenergic pathway (Haas & Kϋbler, 
1997; Sofuoglu et al., 2006; Marano et al., 1999, Wang et al., 2005).   
2. Experimental evidence 
2.1 Overview 
Our previous studies indicated that catecholamines exacerbate the severity of viral 
myocarditis in a murine model (Soodini & Morgan, 2001; Wang & Morgan, 2003; Wang et 
al., 2002a, 2002b, 2005). We performed studies with a variety of agents known to enhance the 
adrenergic tone, all of which exacerbated myocarditis in our viral model; in contrast, 
treatment with propranolol ameliorated the severity of myocarditis. Tobacco smoke has also 
been demonstrated to increase adrenergic activation in animals and patients, in part due to 
its content of nicotine (Cavarra et al., 2001; Pomerleau, 1992; Su, 1982) which in turn may  
exacerbate the severity of viral myocarditis in a murine model through adrenergically 
mediated mechanisms (Bae et al., 2010). As a more generalized hypothesis, exposure to 
tobacco smoke may be an important and as yet underappreciated cause of heart failure in 
patients receiving treatments with pro-inflammatory drugs (i.e. clozapine) or who are 
exposed to pathogens (i.e. viruses) or physical factors (i.e. radiotherapy) that can produce a 
level of myocarditis susceptible to exacerbation.     
Sympathomimetic agents have the potential to produce toxic effects on the heart through a 
variety of mechanisms that are summarized in Figure 1. Note the overlap with mechanisms 
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attributed to tobacco smoke exposure in Table 1, most notably with regard to myocarditis, 
their effects on inflammation, immune function, and factors associated with cardiac and 
vascular dysfunction. Although multiple factors undoubtedly contribute to the exacerbation 
of myocarditis we have observed with tobacco smoke exposure, it is reasonable to propose 
that catecholamine-related effects play a central role. 
 
 
Fig. 1. Direct and indirect effects of catecholamines and related sympathomimetic agents on 
the heart. 
2.2 Propranolol ameliorates and epinephrine exacerbates progression of acute and 
chronic viral myocarditis 
Recent studies point to important interactions between proinflammatory cytokines and 
neurohumoral mediators in heart failure. We investigated the influence of the ǃ-adrenergic 
system on cytokines and neurohumoral factors and the sequelae of viral myocarditis (Wang 
et al., 2005). In an experimental model with virus-infected BALB/c mice, we studied the 
acute and chronic effects of epinephrine and propranolol on myocardial morphology, 
cytokine gene expression, and survival.  BALB/c mice were inoculated with the 
encephalomyocarditis virus (EMCV) or sham inoculated with saline and followed for 30 
days. Epinephrine increased the severity of inflammatory cell infiltration and myocardial 
necrosis induced by EMCV-inoculated mice. Survival rate after  30 days was reduced to 40%  
in epinephrine-treated EMCV-inoculated mice compared with 70% in untreated EMCV-
inoculated mice (P<0.05). Treatment with the ǃ-blocker propranolol significantly decreased 
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mortality, myocardial necrosis and infiltration of inflammatory cells in EMCV-inoculated 
mice. Propranolol also suppressed gene expression of the cytokines TNF-ǂ, IL-6 and IL-10 
involved in inflammation.  A single dose of epinephrine 120 days after EMCV inoculation 
caused death in 70% of infected mice; propranolol significantly reduced the incidence of 
death to 33%. These results indicate that acute and chronic stages of viral myocarditis are 
modulated by the ǃ-adrenergic system and its interactions with proinflammatory factors.   
2.3 Cocaine enhances myocarditis induced by encephalomyocarditis virus in murine 
models 
This study (Wang et al., 2002a) was designed to investigate whether cocaine can exacerbate 
viral myocarditis and increase its incidence. Clinical evidence suggests that cocaine abuse 
increases the incidence of myocarditis. However, it had not been  directly demonstrated that 
cocaine exposure enhances murine myocarditis. BALB/c mice were divided into eight 
groups saline control, encephalomyocarditis virus (EMCV), 10 mg/kg cocaine (Coc-10), 30 
mg/kg cocaine (Coc-30), 50 mg/kg cocaine (Coc-30), EMCV+Coc-50. After inoculation with 
EMCV, the mice were daily treated with either cocaine or saline for 90 days. Mice were 
euthanized at different days after EMCV inoculation. Mortality was recorded and 
myocarditis severity was evaluated. The mortality of the myocarditis mice treated with 
cocaine increased significantly from 22% (EMCV) to 25.7% (Coc-10+ EMCV), 41.4% 9 (Coc-
30+EMCV) and 51.4% (Coc-50+EMCV) (P<0.05) respectively. The incidence and severity of 
inflammatory cell infiltration and myocardial lesions was higher in infected mice exposed to 
cocaine. Cocaine administered only before infection did not exacerbate myocarditis. 
Norepinephrine assay showed that cocaine exposure significantly increased myocardial 
norepinephrine concentration, but this increase was partially inhibited in infected animals. 
Adrenalectomy abolished the effect of cocaine on mortality. Furthermore, propranolol, a ǃ-
blocker, significantly decreased the enhancing effects of cocaine on myocarditis mice. In 
conclusion, cocaine increases the severity and mortality of viral myocarditis in mice. 
Increased catecholamines may be a major factor in this effect.   
A variety of viruses have been reported as causative agents of myocarditis in man, including 
Coxsackie, echo and influenza viruses, cytomegalovirus, poliomyelitis virus, Epstein Barr 
virus, herpes simplex virus, adenovirus and several others (Rodeheffer & Gersh, 2001; 
Ensley et al., 1995; Abelmann, 1966).  Our laboratory has demonstrated that cocaine can 
exacerbate viral myocarditis in a murine model (Wang et al., 2002a). Possible mechanisms of 
such an interaction include, (a) cocaine-induced damage to the endothelial/endocardial cells 
in the extracellular matrix or to the myocytes themselves, thereby reducing structural and 
immunological barriers to cellular penetration of the virus and increasing the myocardial 
and vascular permeability and infectivity of viral particles. Evidence supporting “possibility 
(a)” includes reports suggesting that cocaine can damage the endothelial lining of cells after 
even a single exposure, thereby accelerating atherosclerosis in animal models (Egashira et 
al., 1991; Bacharach et al., 1992). Cocaine has also been reported to increase natural killer cell 
activity (Van Dyke et al., 1986). Both lymphocytic and eosinophilic  myocarditis have been 
reported in cocaine abusers (Virmani et al., 1988; Tazelaar et al., 1987) and heart failure is a 
common finding (Weiner et al., 1986; Duell, 1987). Alternatively, “possibility (b)“, cocaine 
may exacerbate viral myocarditis by permitting enhanced viral replication of the viral agent 
once it has penetrated the cell membrane. Such an effect may occur through a direct or 
catecholamine-mediated alteration in the cellular milieu that in turn could alter viral 
transcription and replication. Enhanced viral replication could occur through a change in 
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cellular pH, shift in osmolarity, or likely depletion of high-energy stores necessary for 
protective proteolytic enzyme activity. Of course, it is likely that the effects of cocaine on the 
animal or a patient with myocarditis are complex and involve several mechanisms or 
conditioning factors, including drug diluents with intrinsic pharmacological activity or 
sensitizing effects (Ensing, 1985; Wolf and Blum, 1983). However, the observation that 
exacerbation of myocarditis seems to occur with cocaine but not other commonly abused 
drugs without prominent cardiac effects, including heroin and phencyclidine, suggests that 
cocaine may have a unique combination of properties that make its use in patients exposed 
or infected with viral pathogens likely to enhance development of myocarditis and its 
sequelae. Our data indicate that the unique ability of cocaine to increase local release and 
circulating levels of catecholamines is the primary factor responsible for exacerbation of 
myocarditis (Ensing, 1985). 
2.4 Clozapine-induced myocarditis: role of catecholamines in a murine model 
Clozapine, an atypical neuroleptic agent, is very effective in the treatment of resistant 
schizophrenia.  However, cardiotoxicity of clozapine, particularly in young patients, has raised 
concerns about its its safety and smoking may have a significant effect on serum 
concentrations of clozapine (Seppala et al., 1999). A particularly high incidence of myocarditis 
has been reported among patients treated with atypical neuroleptic drugs, including clozapine 
and risperidone. Clozapine has been shown to markedly increase circulating levels of 
catecholamines (Coulter et al., 2001; Elman et al., 2002). Increased catecholamines have been 
postulated to trigger an inflammatory response resulting in myocarditis, dilated 
cardiomyopathy, and death, although this has not yet been thoroughly studied. Here (Wang et 
al., 2008), we used the mouse to study whether clozapine administration could caused adverse 
myocarditis associated with an increase in catecholamines. Male BALB/c mice, age ~6 weeks, 
were administered 5, 10 or 25 mg/kg clozapine daily for 7 and 14 days; one group was 
administered 25 mg/kg clozapine plus 2 mg/kg propranolol for 14 days. Saline-treated mice 
served as controls. Heart sections were stained with hematoxylin and eosin for 
histopathological examination. Plasma catecholamines were measured with HPLC. 
Myocardial TNF-ǂ concentrations were determined by ELISA. Histopathologic examination of 
clozapine-treated mice showed a significant dose-related increase in myocardial inflammation 
that correlated with plasma catecholamine levels and release of TNF-ǂ. Propranolol 
significantly attenuated these effects. A hypercatecholaminergic state induced by clozapine 
could explain the occurrence of myocarditis in some patients.  Our data suggest that ǃ-
adrenergic blocking agents may be effective in reducing the incidence and severity of 
clozapine-induced myocarditis.   
3. Tobacco smoke 
3.1 Exacerbation of viral myocarditis by tobacco smoke as a cause of heart failure 
In this study (Bae et al. 2010), we determined whether exposure to tobacco smoke will 
exacerbate the severity of viral myocarditis in mice. Viral myocarditis was generated n 4-
week old male BALB/c mice by ί.ρ. injection of encephalomyocarditis virus (EMCV).  Mice 
were exposed to cigarette smoke for 90 minutes/day 5x/week.  Four groups were studied: 
1) Control (C, no smoke and no virus), 2) Smoke (S) only, and 3) Virus only (V), and 4) Pre-
exposure to smoke for l week prior to virus injection (S+V). We observed an over 2-fold 
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increase in mortality among mice that were pre-exposed to smoke compared to the virus 
alone. Tobacco smoke alone did not affect mortality. There was a significant increase in 
virus load among hearts from mice exposed to S+V compared to V alone. 
In this study, we also investigated the rate of apoptosis 5 days after ί.ρ. injection of virus. 
Viral exposure alone significantly increased the number of apoptotic cells.  The number of  
apoptotic cells was increased further by smoke exposure prior to viral injection.  Viral 
injection increased the translocation of apoptosis-inducing factor from mitochondria, a 
hallmark of caspace-independent apoptosis activation. Exposure to tobacco smoke 
exacerbated these effects without changing the total expression of apoptosis-inducing factor 
suggesting activation of caspace-independent apoptotic pathways as well. 
Apoptosis has been shown to play an important role in human and animal heart failure 
(Kang et al., 2000; Kang & Izumo, 2003). Other investigators have demonstrated EMCV-
induced apoptosis in the hearts of mice and pigs (for example, see Mizutani et al., 1996 and 
Brewer et al., 2001). Activation of caspaces may be a critical facilitator of viral infection in 
cardiomyocytes (DeBiasi et al.,  2004, Kyoto et al., 2004). In fact, DeBiasi et al., have shown 
that inhibition of caspaces effectively blocks virus-induced apoptosis in vitro, although 
caspace-independent factors also appeared to be involved.  Apoptosis-inducing factor 
release from mitochondria is one important caspace-independent factor, and appears to play 
an important role in EMCV-infection related apoptosis, as shown in our study.  These data 
were later to show that viral infection induced a significant increase in apoptosis, through       
caspace-independent apoptosis, and that preexposure to tobacco smoke exacerbated this 
effect.   
Several studies have shown a relationship between myocyte apoptosis and increased 
sympathetic activity in patients with underlying heart disease, most commonly heart failure 
(Singh et al., 2001). Communal et al., 1998 showed that over-stimulation by norepinephrine 
produced apoptosis in ventricular myocytes of adult rats and blocking  the beta-receptor 
decreased apoptosis. These data are consistent with our hypotheses that catecholamines are 
a major factor inducing inflammation and cell death in tobacco smoke exposed animals.   
4. Conclusions 
Evidence from our laboratory and elsewhere (summarized above) indicates that both 
mainstream and secondhand tobacco smoke exposure can exacerbate viral myocarditis. 
Induction of a systemic inflammatory response appears to be a central initiating mechanism 
responsible for myocarditis, an effect that can be mediated by a cardiotropic viral infection 
itself and exacerbated by additional factors, most notably, catecholamines and other 
sympathomimetic agents, (Figure 2). 
There appears to be an additive or synergistic effect of factors producing inflammation, 
which in turn can enhance viral load in the myocytes and exacerbate the extent and severity 
of myocarditis. Severe cardiac dysfunction and clinical heart failure may result.  Our data 
suggest that disruption of gap junctions plays an important role in this regard (Figure 1). 
Moreover, to the extent that catecholamines are responsible, beta-adrenergic antagonists can 
attenuate the effect. Although the results presented in this review are consistent with a 
primary pathogenic role of catecholamines in the exacerbation of myocarditis by tobacco 
smoke, they do not exclude other factors that may operate through different mechanisms. 
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Additional animal and human studies will be necessary to further elucidate the several 
factors that may be involved. However, taken together, the available data indicate that 
tobacco smoke can exacerbate myocarditis which in turn may result in irreversible cardiac 
dysfunction and failure. Even in the absence of additional data, these results provide 
another example of the adverse effects of tobacco smoke and strengthen the argument for 
minimizing exposure to this agent  in our environment. 
 
 
Fig. 2. Proposed primary mechanism for exacerbation of viral myocarditis by tobacco smoke 
exposure: the catecholamine hypothesis. 
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